CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.
about
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritisImmunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabT cell activation and differentiation is modulated by a CD6 domain 1 antibody ItolizumabCD6 as a therapeutic target in autoimmune diseases: successes and challenges.Antibody-based therapeutics to watch in 2011.CD6 attenuates early and late signaling events, setting thresholds for T-cell activationStructures of CD6 and Its Ligand CD166 Give Insight into Their Interaction.Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasisItolizumab in Psoriasis.Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).CD318 is a ligand for CD6.EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.CD6 Receptor Regulates Intestinal Ischemia/Reperfusion-induced Injury by Modulating Natural IgM-producing B1a Cell Self-renewal.The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.Human treg cells are characterized by low/negative CD6 expressionItolizumab (Alzumab), Mogamulizumab (Poteligeo), and Tositumomab (Bexxar)
P2860
Q28728734-EBC09B6A-CFB7-4DD1-AEA1-A628C58B8B84Q33573621-90754046-CC26-41DC-95F4-33667580DF74Q33865748-4E3D8DD3-7082-4F44-BEE8-6654F53B25A5Q34337963-466BD57B-9732-44FB-B7C1-14F364EC6C19Q34570079-28E986D4-05CE-44ED-81EA-7D1066E4F37DQ35818957-E1E9CB65-58BA-4E10-B0EE-E77E45CB2248Q35943010-CA95EE8F-A0FE-47C1-A7FE-7B0CE6782373Q37138277-14281719-2FB8-4C0F-9947-7C450C20A1F3Q37390483-DBAECD7D-2C89-426F-A83C-94C1B93ED8F3Q38461733-699087FA-44BB-4655-AAF4-7534F86BA00BQ38631525-EE234978-050D-4A88-829A-E6A6F2E582D7Q38726869-7D4C72B4-7B3E-4F1E-9364-515848962C00Q38856226-AD706BCA-A488-41FD-9CCA-72127469499DQ41476987-EE068589-FBF2-41C5-8ACC-44FC36282996Q41855293-3DA2D2DD-A417-494F-B7D5-5585D14D846FQ48023143-AE23C8E9-7628-47F9-B99F-E241C2D1B8A7Q48265755-C46A3581-A87D-4759-B091-CF9DD88EEA59Q56896657-96F6196C-35FE-42FD-823C-56A477BEB918Q58008014-156DD3F6-2EE9-44D6-898C-312263D7A40E
P2860
CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
CD6 synergistic co-stimulation ...... adhesion molecule interaction.
@en
type
label
CD6 synergistic co-stimulation ...... adhesion molecule interaction.
@en
prefLabel
CD6 synergistic co-stimulation ...... adhesion molecule interaction.
@en
P2093
P2860
P1476
CD6 synergistic co-stimulation ...... adhesion molecule interaction.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2249.2010.04235.X
P577
2010-08-19T00:00:00Z